Anton Rx Report

Here’s something that you don’t see every day….. CVS has announced that it is opening a new division to provide Clinical Trial Services. Yep, the

The FDA recently approved a new Specialty Infusion therapy, Rybrevant (amivantamab-vmjw) from Janssen Pharmaceutical, as the first treatment for adult patients with non-small cell lung

We recently expressed our disappointment in the meager annual pharmacy trend reports now being offered by the leading PBMs. They once were the most insightful

Last week the FDA approved a new sub-q therapy, Empaveli (pegcetacoplan) from Apellis Pharmaceuticals, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who

We are always on the lookout for updates on health systems that own or operate their own specialty pharmacies as well as third-party organizations that

Today we now better understand how UBER costly drugs, such as the big-ticket CAR-T therapies, are billed and paid for in our highly fractional health

Over the years I’ve been able to visit dozens of specialty pharmacies working with pharmacy leadership to help develop new programs. Each of these new

How time flies!About three years ago Amazon jumped into the prescription business throwing a new monkey wrench in the segment. So, what’s happened in that

Were there fireworks to mark the event?Was there a parade to commemorate the long-awaited day?In short, NO! Annual Drug Trend Reports from Express Scripts (Evernorth)

The FDA approved a new infused specialty therapy last week, Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics, for the treatment of adult patients with relapsed or